TipRanks (Sun, 7-Jun 8:40 PM ET)
PRNewswire (Thu, 4-Jun 6:26 AM ET)
PRNewswire (Wed, 3-Jun 7:26 AM ET)
PRNewswire (Mon, 18-May 7:27 AM ET)
Elanco to Participate in Upcoming Investor Conferences
PRNewswire (Thu, 14-May 8:00 AM ET)
Elanco Animal Health Reports First Quarter 2026 Results
PRNewswire (Wed, 6-May 5:20 PM ET)
/C O R R E C T I O N -- Elanco Animal Health/
PRNewswire (Tue, 28-Apr 7:04 PM ET)
PRNewswire (Mon, 27-Apr 6:24 PM ET)
National Veterinary Associates Appoints Todd S. Young as Chief Financial Officer
Business Wire (Fri, 24-Apr 9:00 AM ET)
Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement
PRNewswire (Thu, 16-Apr 8:00 AM ET)
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
Elanco Animal Health trades on the NYSE stock market under the symbol ELAN.
As of June 9, 2026, ELAN stock price climbed to $24.50 with 4,802,543 million shares trading.
ELAN has a beta of 1.38, meaning it tends to be more sensitive to market movements. ELAN has a correlation of 0.18 to the broad based SPY ETF.
ELAN has a market cap of $12.24 billion. This is considered a Large Cap stock.
Last quarter Elanco Animal Health reported $1 billion in Revenue and $.40 earnings per share. This beat revenue expectation by $95 million and exceeded earnings estimates by $.06.
In the last 3 years, ELAN traded as high as $27.72 and as low as $8.02.
The top ETF exchange traded funds that ELAN belongs to (by Net Assets): IJH, VTI, VB, VBR, VXF.
ELAN has outperformed the market in the last year with a price return of +76.3% while the SPY ETF gained +24.3%. However, in the short term, ELAN had mixed performance relative to the market. It has underperformed in the last 3 months, returning +4.9% vs +9.9% return in SPY. But in the last 2 weeks, ELAN shares have fared better than the market returning +12.7% compared to SPY -1.2%.
ELAN support price is $22.83 and resistance is $24.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELAN shares will trade within this expected range on the day.
